Regeneron Pharmaceuticals Net Income Over Time
REGN Stock | USD 957.00 19.39 2.07% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Regeneron Pharmaceuticals Performance and Regeneron Pharmaceuticals Correlation. Regeneron |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Earnings Share 34.77 | Revenue Per Share 122.935 | Quarterly Revenue Growth 0.006 | Return On Assets 0.0849 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Regeneron Pharmaceuticals and related stocks such as Crispr Therapeutics, Novo Nordisk AS, and Sarepta Therapeutics Net Income Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CRSP | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (25.8 M) | (23.2 M) | (68.4 M) | (165 M) | 66.9 M | (348.9 M) | 377.7 M | (650.2 M) | (153.6 M) | (161.3 M) |
NVO | 607.8 M | 17.1 B | 21.4 B | 25.2 B | 26.5 B | 34.9 B | 37.9 B | 38.1 B | 38.6 B | 39 B | 42.1 B | 47.8 B | 55.5 B | 83.7 B | 87.9 B |
SRPT | (2.6 M) | (2.3 M) | (121.3 M) | (112 M) | (135.8 M) | (220 M) | (267.3 M) | (50.7 M) | (361.9 M) | (715.1 M) | (554.1 M) | (418.8 M) | (703.5 M) | (536 M) | (509.2 M) |
NTLA | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (12.4 M) | (31.6 M) | (67.5 M) | (85.3 M) | (92.7 M) | (125.6 M) | (259.7 M) | (490.2 M) | (481.2 M) | (457.1 M) |
INCY | (4.9 M) | (186.5 M) | (44.3 M) | (83.1 M) | (48.5 M) | 6.5 M | 104.2 M | (313.1 M) | 109.5 M | 446.9 M | (295.7 M) | 948.6 M | 340.7 M | 597.6 M | 627.5 M |
ALNY | (4.1 M) | (57.6 M) | (106 M) | (89.2 M) | (360.4 M) | (290.1 M) | (410.1 M) | (490.9 M) | (761.5 M) | (886.1 M) | (858.3 M) | (852.8 M) | (1.1 B) | (440.2 M) | (462.3 M) |
UTHR | (12.8 M) | 217.9 M | 304.4 M | 174.6 M | 340.1 M | 651.6 M | 713.7 M | 417.9 M | 589.2 M | (104.5 M) | 514.8 M | 475.8 M | 727.3 M | 984.8 M | 1 B |
RARE | (6.8 M) | (6.8 M) | (16.3 M) | (35.1 M) | (59.8 M) | (145.6 M) | (245.9 M) | (302.1 M) | (197.6 M) | (402.7 M) | (186.6 M) | (454 M) | (707.4 M) | (606.6 M) | (576.3 M) |
APLS | (4 M) | (4 M) | (4 M) | (4 M) | (10.8 M) | (46.5 M) | (27.1 M) | (51 M) | (127.5 M) | (309.8 M) | (344.9 M) | (746.4 M) | (652.2 M) | (528.6 M) | (502.2 M) |
PTCT | 30.9 M | 30.9 M | (26.2 M) | (51.6 M) | (93.8 M) | (170.4 M) | (142.1 M) | (79 M) | (128.1 M) | (251.6 M) | (438.2 M) | (523.9 M) | (559 M) | (626.6 M) | (595.3 M) |
KRYS | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (7.9 M) | (10.9 M) | (19.1 M) | (32.2 M) | (69.6 M) | (140 M) | 10.9 M | 11.5 M |
MDGL | (381 K) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.2 M) | (32.8 M) | (72.8 M) | (197.4 M) | (241.1 M) | (299.3 M) | (373.6 M) | (354.9 M) |
BGNE | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (18.3 M) | (57.1 M) | (119.2 M) | (93.1 M) | (673.8 M) | (950.6 M) | (1.6 B) | (1.4 B) | (2 B) | (881.7 M) | (925.8 M) |
BMRN | (12.3 M) | (53.8 M) | (114.3 M) | (176.4 M) | (134 M) | (171.8 M) | (630.2 M) | (117 M) | (77.2 M) | (23.8 M) | 854 M | (64.1 M) | 141.6 M | 167.6 M | 176 M |
ARWR | (854.5 K) | (21.1 M) | (31.1 M) | (58.6 M) | (91.9 M) | (81.7 M) | (34.4 M) | (54.5 M) | 68 M | (84.6 M) | (140.8 M) | (176.5 M) | (205.3 M) | (184.7 M) | (175.5 M) |
IONS | (4.5 M) | (84.8 M) | (65.5 M) | (60.6 M) | (39 M) | (88.3 M) | (86.6 M) | (6 M) | 273.7 M | 294 M | (487 M) | (29 M) | (270 M) | (366.3 M) | (348 M) |
Regeneron Pharmaceuticals and related stocks such as Crispr Therapeutics, Novo Nordisk AS, and Sarepta Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Regeneron Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Regeneron Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
Regeneron Pharmaceuticals | REGN |
BiotechFama & French Classification | |
Location | New York; U.S.A |
Exchange | NASDAQ Exchange |
USD 957.0
Check out Regeneron Pharmaceuticals Performance and Regeneron Pharmaceuticals Correlation. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Regeneron Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.